CRDF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cardiff Oncology Inc (CRDF) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available. While the company has promising developments in its pipeline, the lack of immediate catalysts, weak technical indicators, and declining financial performance suggest that waiting for further clarity on its clinical trials or financial improvement would be prudent.
The MACD is slightly positive but contracting, indicating weak momentum. RSI is neutral at 38.515, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 1.775 and resistance at 2.023. Overall, the technical indicators suggest a weak trend.
Analysts from H.C. Wainwright and Noble Capital see long-term potential, with price targets of $10 and $12, respectively.
The company's lead drug candidate, onvansertib, is being developed for aggressive cancer types, which could be a significant breakthrough if successful.
Revenue increased by 60.93% YoY in Q4 2025.
Piper Sandler reduced the price target from $10 to $6, citing delays in drug approval timelines.
Net income and EPS have declined significantly YoY, indicating financial strain.
No recent news or significant insider/hedge fund activity to support a near-term rally.
In Q4 2025, revenue increased by 60.93% YoY to $243,000, but net income dropped by -38.75% YoY to -$7.22M, and EPS fell by -50.00% YoY to -0.11. Gross margin remained stable at 100%. The company has cash reserves of $58.3M, sufficient to fund operations into Q1 2027.
Analysts are mixed but leaning positive. Piper Sandler lowered the price target to $6, citing delays in drug approval. H.C. Wainwright and Noble Capital maintain Buy/Outperform ratings with price targets of $10 and $12, respectively, based on long-term potential. However, the timeline for clinical trial results and drug approval is extended, reducing near-term catalysts.
